High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland

AIDS Research and Human Retroviruses

Volumn 15, Issue 8, 1999, Pages 699-705

  Egan, John Fergal ^a   O'Leary, Bronagh ^a   Lewis, Martha J ^a,b   Mulcahy, Fiona ^c   Sheehy, Noreen ^a   Hasegawa, Hideki ^a   Fitzpatrick, Fidelma ^c   O'Connor, John J ^d   O'Riordan, Joan ^e   Hall, William W ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ROCKEFELLER UNIVERSITY   (United States)

^c ST JAMES S HOSPITAL   (Ireland)

^d Trinity Court Drug Treatment Centre ^*  (Ireland)

^e IRISH BLOOD TRANSFUSION SERVICE   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COMORBIDITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN T CELL LEUKEMIA VIRUS 2; INTRAVENOUS DRUG ABUSE; IRELAND; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; VIRUS CHARACTERIZATION; VIRUS DETECTION; VIRUS GENE;

ADULT; BLOTTING, WESTERN; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HIV-1; HTLV-II ANTIBODIES; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; IRELAND; MALE; PHYLOGENY; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SUBSTANCE ABUSE, INTRAVENOUS; TERMINAL REPEAT SEQUENCES; VIRAL ENVELOPE PROTEINS;

EID: 0033586970     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310782     Document Type: Article

References (48)

1. Hall WW, Kubo T, Ijichi S, Takahashi T, and Zhu SW: Human T-cell leukemia/lymphoma virus, type II (HTLV-II): Emergence of an important newly recognized pathogen. Semin Virol 1994;5:165-178.
2. Hollsberg P and Hafler DA: Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type-I infection. N Engl J Med 1993;328:1173-1182.
3. Hinuma Y, Komoda H, Chosa T, Kondo T, Kohakura M, Takenaka T, Kikuchi M, Ichimaru M, Yunoki K, Sato I, Mtsuo R, Takiuchi Y, Uchino H, and Hanoka M: Antibodies to adult T cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: A nation-wide sero-epidemiological study. Int J Cancer 1982;29:631-635.
4. Kajiyama W, Kashiwagi S, Monura H, Ikematsu H, Hayashi J, and Ikematsu W: Seroepidemiological study of antibody to adult T cell leukemia virus in Okinawa, Japan. Am J Epidemiol 1986;123:41-47.
5. Blattner WA, Saxinger C, Riedel D, Hull B, Taylor G, Cleghorn F, Gallo R, Blumberg B, and Bartholomew C: A study of HTLV-I and its associated risk factors in Trinidad and Tobago. J AIDS 1990;3:1102-1108.
6. Murphy EL, Figueroa JP, Gibbs WN, Holding-Cobham M, Cranston B, Malley K, Bodner AJ, Alexander SS, and Blattner WA: Human T lymphotropic virus type-I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants. Am J Epidemiol 1991;133:1114-1124.
7. Saxinger W, Blattner WA, Levine PH, Biggar R, Hoh M, Moghissi J, Jacobs P, Wilson L, Jacobson R, Crookes R, Strong M, Ansari AA, Dean AG, Nkrumah FK, Mourali N, and Gallo RC: Human T-leukemia virus (HTLV-I) antibodies in Africa. Science 1984;225:1473-1476.
8. Verdier M, Denis F, Sangare A, Barin F, Gershy-Damet G, Rey JL, Soro B, Leonard G, Mounier M, and Hugon J: Prevalence of antibody to human T cell leukemia virus type-I (HTLV-I) in populations of Ivory Coast. J Infect Dis 1989;160:363-370.
9. Yoshida M, Miyoshi I, and Hinuma Y: Isolation and characterization of retrovirus from cell lines of human T cell leukemia and its implications in the disease. Proc Natl Acad Sci USA 1982;79:2031-2035.
10. Takatsuki K: Adult T cell leukemia. Intern Med 1995;34:947-952.
11. Gessain A, Barin F, Vemant JC, Gout O, Maurs L, Calender A, and de Thé G: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407-410.
12. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, and Tara M: HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1:1031-1032.
13. Mochizuki M, Watanabe T, Yamaguchi K, Takatsuki K, Yoshimura K, Shiaro M, Nakashima S, Mon S, Araki S, and Miyata N: HTLV-I uveitis: A distinct clinical entity caused by HTLV-I. Jpn J Cancer 1992;83:236-239.
14. Nakao K and Ohba N: Clinical features of HTLV-I associated uveitis. Br J Ophthalmol 1993;77:274-279.
15. Hjelle B, Scalf R, and Swenson S: High frequency of human T cell leukemia-lymphoma virus type-II in New Mexico blood donors: Determination by sequence-specific oligonucleotide hybridization. Blood 1990;76:450-454.
16. Levin PH, Jacobson S, Elliot R, Cavallero A, Colclough G, Dorry C, Stephenson C, Knigge RM, Drummond J, Nishimura M, Taylor ME, Wiktor S, and Shaw GM: HTLV-II infection in Florida Indians. AIDS Res Hum Retroviruses 1993;9:123-127.
17. Maloney EM, Biggar RJ, Neel JV, Taylor ME, Hahn BH, Shaw GM, and Blattner WA: Endemic human T cell lymphotropic virus type-II infection among isolated Brazilian Amerindians. J Infect Dis 1992;166:100-107.
18. The HTLV European Research Group: Seroepidemiology of the human T cell leukemia-lymphoma viruses in Europe. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:68-77.
19. Fukushima Y, Takahashi H, Hall WW, Nakasone T, Nakata S, Song P, Due DD, Hien B, Quang NX, Trinh TH, Nishioka K, Kitamura K, Komuro K, Vahlne A, and Honda M: Extraordinary high rate of HTLV type II seropositivity in intravenous drug abusers in South Vietnam. AIDS Res Hum Retroviruses 1995;11:637-644.
20. Hall WW, Ishak R, Zhu SW, Novoa P, Eriaku N, Takahashi H, da Costa Ferreira M, Azevedo V, Ishak MOG, da Costa Ferreira O, Monken C, and Kurata T: Human T lymphotropic virus type-II (HTLV-II): Epidemiology, molecular properties, and clinical features of infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl. 1):S204-S214.
21. Hjelle B, Appenzeller O, Mills R, Alexander S, Torrez-Martinez N, Jahnke R, and Ross G: Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 1992;339:645-646.
22. Berger JR, Svenningsson A, Raffanti S, and Resnick L: Tropical spastic paraparesis-like illness occurring in a patient dually infected with HIV-1 and HTLV-II. Neurology 1991;41(1):85-87.
23. Harrington WJ Jr, Sheremata W, Hjelle B, Dube DK, Bradshaw P, Foung SK, Snodgrass S, Toedter G, Cabrai L, and Poiesz B: Spastic ataxia associated with human T-cell lymphotropic virus type II infection. Ann Neurol 1993;33(4):411-414.
24. Sheremata WA, Harrington WJ Jr, Bradshaw PA, Foung SK, Raffanti SP, Berger JR, Snodgrass S, Resnick L, and Poiesz BJ: Association of "(tropical) ataxic neuropathy" with HTLV-II. Virus Res 1993;29(1):71-77.
25. Jacobson S, Lehky T, Nishimura M, Robinson S, McFarlin DE, and Dhib-Jalbut S: Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann Neurol 1993;33(4):392-396.
26. Murphy EL, Engstrom JW, Miller K, Sacher RA, Busch MP, and Hollingsworth CG: HTLV-II associated myelopathy in 43-year-old woman. Lancet 1993;341(8847):757-758.
27. Murphy EL, Fridey J, Smith JW, Engstrom J, Sacher RA, Miller K, Gibble J, Stevens J, Thomson R, Hansma D, Kaplan J, Khabbaz R, and Nemo G: HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. Neurology 1997;48 (2):315-320.
28. Calabro ML, Luparello M, Grottola A, Del Mistro A, Fiore JR, Angarano G, and Chieco-Bianchi L: Detection of human T lymphotropic virus type IIb in human immunodeficiency virus type 1-coinfected persons in southeastern Italy. J Infect Dis 1993;168:1273-1277.
29. Salemi M, Cattaneo E, Casoli C, and Bertazzoni U: Identification of IIa and IIb molecular subtypes of human T-cell lymphotropic virus type II among Italian injecting drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8(5):516-520.
30. Ferrante P, Mancuso R, Zuffolato R, Puricelli S, Mannella E, Romano L, Zanetti A, Cattaneo E, and Corrao V: Molecular analysis of HTLV-I and HTLV-II isolates from Italian blood donors, intravenous drug users and prisoners. New Microbiol 1997;20(2):93-104.
31. Zella D, Cavicchini A, Salemi M, Casoli C, Lori F, Achilla G, Cattaneo E, Landini V, and Bertazzoni U: Molecular characterization of two isolates of human T cell leukaemia virus type II from Italian drug abusers and comparison of genome structure with other isolates. J Gen Virol 1993;74(3):437-444.
32. Chironna M, Calabro ML, Quarto M, Germinario C, Fiore JR, Favero A, Potenza D, Chieco-Bianchi L, and Barbuti S: HTLV-I and HTLV-II infections in subjects at risk for HIV-1 infection from southeastern Italy (Apuilia region). Int J Cancer 1996;65(6):746-750.
33. Vallejo A and Garcia-Saiz A: HTLV-II subtype b among injecting drug users in Spain. Vox Sang 1994;67:81-82.
34. Henrard DR, Soriano V, Robertson E, Gutierrez M, Stephens J, Dronda F, Miles F, Pujol E, Buytendorp M, and Castro A: Prevalence of human T-cell lymphotropic virus type-I (HTLV-I) and HTLV-2 infection among Spanish drug users measured by HTLV-I assay and HTLV-I and 2 assay. HTLV-I and HTLV-2 Spanish Study Group. J Clin Microbiol 1995;33:1735-1738.
35. Soriano V, Vallejo A, Gutierrez M, Tuset C, Cilia G, Martines-Zapico R, Dronda F, Caballero E, Calderon E, Aguilera A, Martin AM, Llibre J, del Romero J, Ortiz de Lejarazu R, Ulloa F, Eiros J and Gonzalez-Lahoz J: Epidemiology of human T-lymphotropic virus type D (HTLV-II) infection in Spain. HTLV Spanish Study Group. Eur J Epidemiol 1996;12:625-629.
36. Soriano V, Gutierrez M, Vallejo A, Tuset C, Dronda F, and Pujol E: HTLV-II infection in Spain. Analysis of 113 cases identified until November, 1994. Spanish Group for the Study of HTLV/I/II. Med Clin (Barcelona) 1995;105:251-254.
37. Vallejo A, Casado C, Canto C, Varela JM, Barge T, Rabella N, Herrera MI, and Garcia Saiz A: Isolation, sequencing and ultrastructure of HTLV-I and HTLV-II. Presence of the HTLV-II subtype b among Spanish intravenous drug addicts. Med Clin (Barcelona) 1994;103:730-736.
38. Vallejo A, Ferrante P, Soriano V, Calabro ML, Mancuso R, Heredia A, Mannella E, Favero A, Garcia-Saiz A, Chieco-Bianchi L, Gonzalez-Lahoz J, and Hewlett IK: Nucleotide sequence and restriction fragment-length polymorphism analysis of human T-cell lymphotropic virus type II (HTLV-II) in southern Europe: Evidence for the HTLV-IIa and HTLV-IIb subtypes. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:384-391.
39. Anderson S, Ahmed R, Bredberg-Raden U, Albert J, Krook A, Kall K, Biberfield G, and Popovic M: HTLV-II infected Swedish intravenous drug abusers carry subtype. A. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:280.
40. Lee H, Swanson P, Shorty VS, Zack JA, Rosenblatt JD, and Chen ISY: High rate of HTLV-II infection in Seropositive IV drug abusers in New Orleans. Science 1989;244:471-475.
41. Hall WW, Takahashi H, Liu C, Kaplan MH, Scheewind O, Ijichi S, Nagashima K, and Gallo RC: Multiple isolates and characteristics of human T-cell leukemia type-II. J Virol 1992;66(4):2456-2463.
42. Vandamme AM, Liu HF, Van Brussel M, De Meurichy W, Desmyter J, and Goubau P: The presence of a divergent T-lymphotropic virus in a wild-caught pygmy chimpanzee (Pan paniscus) supports an African origin for the human T-lymphotropic/simian T-lymphotropic group of viruses. J Gen Virol 1996;77:1089-1099.
43. Vandamme AM, Salemi M, Van Brussel M, Liu HF, Van Laethem K, Van Ranst M, Michels L, Desmyter J, and Goubau P: African origin of human T-cell lymphotropic virus type 2 (HTLV-2) supported by a potential new HTLV-2d subtypes in Congolese Bambuti Efe pygmy. J Virol 1998;72(5):4327-4340.
44. Murphy EL, Mahieux R, de The G, Tekaia F, Ameti D, Horton J, and Gessain A: Molecular epidemiology of HTLV-II among United States blood donors and intravenous drug users: An age-cohort effect for HTLV-II RFLP type aO. Virology 1998;242(2):425-434.
45. Salemi M, Vandamme AM, Gradozzi c, Van Laethem K, Cattaneo E, Taylor G, Casoli C, Goubau P, Desmyter J, and Bertazzoni U: Evolutionary rate and genetic heterogeneity of human T-cell lymphotropic virus type II (HTLV-II) using isolates from European injecting drug users. J Mol Evol 1998;46(5):602-611.
46. Blomberg J, Moestrup T, Frimand J, Hansson BG, Krogsgaard K, Grillner L, and Nordenfelt E: HTLV-I and HTLV-II in intravenous drug users from Sweden and Denmark. Scand J Infect Dis 1994;26(1):23-26.
47. Andersson S, Krook A, Kall K, Julander I, Thorstensson R, and Biberfeld G: HTLV infections among Swedish intravenous drug users in 1992. Scand J Infect Dis 1995;27:547-550.
48. Krook A and Blomberg J: HTLV-II among injecting drug users in Stockholm. Scand J Infect Dis 1994;26:129-132.